BioAtla Inc Stock News

45% overall response rate (ORR) and a 100% disease control rate (DCR) in HPV+ OPSCC patients treated with a median of 3 prior lines of therapy Marked unmet need exists in 2L+ HPV+ OPSCC patients; standard of care agents (methotrexate, docetaxel, or cetuximab) report an ORR of 3.4% Plan to finalize Phase 3 trial design in 2L+ HPV+ OPSCC with the U.S. Food and Drug Administration (FDA) SAN DIEGO,...

BioAtla, Inc. (NASDAQ:BCAB ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, Investor Relations Jay Short - Chairman, Chief Executive Officer and Cofounder Richard Waldron - Chief Financial Officer Eric Sievers - Chief Medical Officer Sheri Lydick - Chief Commercial Officer Conference Call Participants Jeet Mukherjee – BTIG Reni Benj...

SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the first quarter ended March 31, 2025 and provided highlights on its clinical programs.

SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company's management will provide a corporate update and participate in one-on-one investor meetings at the Citizens Life Scien...

SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, May 6, 2025 at 4:30 p.m. ET to discuss its financial results for the fir...

SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced preclinical poster presentations at the upcoming 2025 American Association for Cancer Research (AACR) to be held at the McCormick Place ...

SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting to be held online and at the McCo...

BioAtla, Inc. (NASDAQ:BCAB ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, Investor Relations Jay Short - Chairman, Chief Executive Officer and Cofounder Richard Waldron - Chief Financial Officer Eric Sievers - Chief Medical Officer Sheri Lydick - Chief Commercial Officer Conference Call Participants Jeet Mukherjee - BTIG Tony B...